Cargando…
BIMG-13. A NOVEL RADIOPHARMACEUTICAL ([(18)F]DASA-23) TO MONITOR PYRUVATE KINASE M2 INDUCED GLYCOLYTIC REPROGRAMMING IN GLIOBLASTOMA
BACKGROUND: Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, a key process of cancer metabolism. PKM2 is preferentially expressed by glioblastoma (GBM) cells with minimal expression in healthy brain, making it an important biomarker of cancer glycolytic re-programming. We describe t...
Autores principales: | Beinat, Corinne, Patel, Chirag, Haywood, Tom, Murty, Surya, Naya, Lewis, Hayden-Gephart, Melanie, Khalighi, Mehdi, Massoud, Tarik, Iagaru, Andrei, Davidzon, Guido, Thomas, Reena, Nagpal, Seema, Recht, Lawrence, Gambhir, Sanjiv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992247/ http://dx.doi.org/10.1093/noajnl/vdab024.012 |
Ejemplares similares
-
BIMG-16. TRACKING TTFIELDS-INDUCED ALTERATIONS IN GLIOBLASTOMA METABOLISM WITH [18F]DASA-23, A NON-INVASIVE PROBE OF PYRUVATE KINASE M2 (PKM2)
por: Patel, Chirag, et al.
Publicado: (2021) -
Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [(18)F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression
por: Patel, Chirag B., et al.
Publicado: (2020) -
Tethered together: DASA design towards aqueous compatibility
por: Peterson, Julie A., et al.
Publicado: (2023) -
(18)F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT
por: Baratto, Lucia, et al.
Publicado: (2017) -
Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality
por: Sonni, Ida, et al.
Publicado: (2018)